Matt Hellmann/astrazeneca.com
Apr 27, 2025, 12:36
Matt Hellmann: Great to be heading back to Chicago for AACR25
Matt Hellmann, Vice President of Early Oncology Development at AstraZeneca, posted on LinkedIn:
“Great to be heading back to Chicago for AACR25 to share the wealth of AstraZeneca early oncology data with researchers and scientists as we seek to transform care for patients.
We will be making six first disclosures across six novel modalities at this year’s meeting. I’m proud of my early oncology development team and the scientific advances they are making. These data are a strong foundation for our ambitious 2030 goals as we continue to progress the development of our assets.
I’m particularly looking forward to the four first disclosures that focus on prostate cancer – the most common cancer in men, with cases expected to double by 2040. It remains an area of immense unmet need.
Every day we strive to deepen our understanding of the biology behind cancer, working to develop new medicines from which patients may potentially benefit. I look forward to connecting with everyone as we continue to transform care for patients, taking a step closer to our ultimate ambition of eliminating cancer as a cause of death.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 27, 2025, 12:36
Apr 27, 2025, 12:29
Apr 27, 2025, 12:28
Apr 27, 2025, 12:20
Apr 27, 2025, 12:20
Apr 27, 2025, 12:09
Apr 27, 2025, 11:20